Clinical trial
Safety and Efficacy Study of Phenoptin in Subjects With Hyperphenylalaninemia…
NCT00355264 · BioMarin Pharmaceutical, Industry · Completed
Key facts
| NCT number | NCT00355264 |
|---|---|
| Title | Safety and Efficacy Study of Phenoptin in Subjects With Hyperphenylalaninemia Due to BH4 Deficiency |
| Official title | Phase 2, Multicenter, Open Label Study of Phenoptin in Subjects With Hyperphenylalaninemia Due to Primary BH4 Deficiency |
| Lead sponsor | BioMarin Pharmaceutical, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Tetrahydrobiopterin Deficiencies, Hyperphenylalaninemia, Non-Phenylketonuric |
| Intervention type | Drug |
| Interventions | Phenoptin |
| Enrollment | 12 |
| Start date | Aug 1, 2006 |
| Primary completion | Jun 1, 2009 |
| Completion | Jun 1, 2009 |
| First posted | Jul 21, 2006 |
| Last update posted | Sep 25, 2020 |
| Countries | Germany, United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: